Jazz’s Chimerix buy faces its big test.
ApexOnco Front Page
Recent articles
The first data are dribbled out, but cross-trial comparisons look uninspiring.
Supply continues to cause headaches for radiopharmaceutical developers.
As the dust settles on ASCO the weekend’s immediate winners and losers emerge.
A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.
The group is keeping faith with the novel target KLK2.
Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.
The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.